Top Markets
Coin of the day
Oragenics, Inc. Oragenics, Inc.

Oragenics, Inc.

OGEN
Rankning i aktier #36713
Oragenics, Inc. (OGEN) is a U.S.-based biotechnology firm primarily focused on... Oragenics, Inc. (OGEN) is a U.S.-based biotechnology firm primarily focused on creating treatments for infectious diseases. Among its pipeline assets are two vaccine candidates designed to combat the novel severe acute respiratory syndrome coronavirus (SARS-CoV-2): NT-CoV2-1, an intranasal formulation, and Terra CoV-2, an intramuscular option. Beyond its infectious disease focus, Oragenics also has other experimental treatments under development, including LPT3-04, targeting weight loss, and SMaRT Replacement Therapy, a topical solution aimed at preventing dental cavities. Strategic alliances are also a part of its operations. This includes a licensing deal with Noachis Terra Inc. for patents and biological resources related to pre-fusion coronavirus spike proteins. Additionally, Oragenics is collaborating with Precigen, Inc. and ILH Holdings, Inc. on the advancement and market introduction of MU1140 and its associated compounds. Established in 1996, the company, formerly known as Oragen, Inc., maintains its headquarters in Tampa, Florida.
Aktiekurs
$0.5301
Senast synkroniserad: 2026-08-14
Marknadsvärde
$2.39M
Förändring (1 dag)
0.00%
Förändring (1 år)
-53.90%
Land
US
Handel Oragenics, Inc. (OGEN)

Kategori

Utdelningsavkastning för Oragenics, Inc. (OGEN)
Utdelningsavkastningen (TTM) för Oragenics, Inc. (aktiesymbol: OGEN) per 2026 är: 0
Genomsnittlig utdelningsavkastning de senaste 5 åren: 0.00%
Historik för utdelningsavkastning för Oragenics, Inc. (OGEN) från 2026 till 2026
Utdelningsavkastning i slutet av varje år (TTM)
År Utdelningsavkastning Ändra
Inte tillräckligt med data för de angivna datumen.
Utdelningsavkastning (TTM) för liknande företag eller konkurrenter